Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Micardis Expanded Prophylactic Indication Faces Safety Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s cardio-renal advisory committee meets July 29 to assess comparative data to ramipril (the now generic Altace).

You may also be interested in...

King’s Cardiac Imaging Drug Binodenoson Gets Committee Review

CorVue would compete with Astellas’ Lexiscan in a market that has seen many product development failures recently.

BI/Abbott Will Promote Micardis and Mobic With 1,200 Sales Reps

Abbott/Boehringer Ingelheim's combined promotional force for Micardis will total 1,200 sales reps when joint promotional efforts begin in April.

US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts